Technical Analysis for NTLA - Intellia Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 16.16 -8.29% -1.46
NTLA closed down 8.29 percent on Friday, March 22, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical NTLA trend table...

Date Alert Name Type % Chg
Mar 22 Bearish Engulfing Bearish 0.00%
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 Slingshot Bullish Bullish Swing Setup 0.00%
Mar 21 New Uptrend Bullish -8.29%
Mar 21 Reversal New Highs Setup Bullish Swing Setup -8.29%
Mar 21 Outside Day Range Expansion -8.29%
Mar 21 Up 3 Days in a Row Strength -8.29%
Mar 21 Up 4 Days in a Row Strength -8.29%
Mar 21 Up 5 Days in a Row Strength -8.29%
Mar 20 NR7 Range Contraction -4.72%

Older signals for NTLA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Medicine Biotechnology Biology Alpha Immune System Emerging Technologies Molecular Biology Genetics Inborn Errors Of Metabolism Antitrypsin Deficiency Chimeric Antigen Receptor Genome Editing Cas9 CRISPR Liver Diseases Transthyretin Amyloidosis
Is NTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 32.95
52 Week Low 11.03
Average Volume 620,921
200-Day Moving Average 21.629
50-Day Moving Average 14.84
20-Day Moving Average 16.1695
10-Day Moving Average 16.705
Average True Range 0.9298
ADX 25.03
+DI 26.9243
-DI 17.0043
Chandelier Exit (Long, 3 ATRs ) 14.9706
Chandelier Exit (Short, 3 ATRs ) 15.5794
Upper Bollinger Band 17.8324
Lower Bollinger Band 14.5066
Percent B (%b) 0.5
BandWidth 20.568354
MACD Line 0.6261
MACD Signal Line 0.6163
MACD Histogram 0.0098
Fundamentals Value
Market Cap 583.57 Million
Num Shares 36.1 Million
EPS -1.33
Price-to-Earnings (P/E) Ratio -12.15
Price-to-Sales 42.05
Price-to-Book 5.07
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.44
Resistance 3 (R3) 18.68 18.16 18.06
Resistance 2 (R2) 18.16 17.58 18.04 17.93
Resistance 1 (R1) 17.16 17.22 16.90 16.92 17.81
Pivot Point 16.64 16.64 16.51 16.52 16.64
Support 1 (S1) 15.64 16.06 15.38 15.40 14.51
Support 2 (S2) 15.12 15.70 15.00 14.39
Support 3 (S3) 14.12 15.12 14.26
Support 4 (S4) 13.88